In order to establish a supporting control system for synthetic lethality screening of ERα-negative breast cancer cells (of the TN subgroup), two human epithelial breast carcinoma cell lines, BT549 and MDA-MB-231, were initially utilized as recipients for the ERα-expressing constructs. This evidence concerns the gene ERAL1 and breast carcinoma.